Marianne De Backer (L) and Jeff Hatfield

Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO con­ga line

Vi­vid­ion is can­cel­ing that IPO it filed. In­stead of fol­low­ing the in­dus­try-wide mi­gra­tion to Nas­daq, the biotech that has cap­tured con­sid­er­able at­ten­tion for its still-pre­clin­i­cal work find­ing cryp­tic pock­ets to bind to on pro­teins is go­ing to work for Bay­er now.

The phar­ma gi­ant is putting out word to­day that it has bought out Vi­vid­ion for $1.5 bil­lion in cash and an­oth­er half-bil­lion dol­lars in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.